Genetic Testing Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 24.45 Bn

Forecast Year, 2035

USD 71.09 Bn

CAGR, 2026 - 2035

11.26%

Report Coverage

Global

What is the Genetic Testing Market Size?

The global genetic testing market size is calculated at USD 24.45 billion in 2025 and is predicted to increase from USD 27.32 billion in 2026 to approximately USD 71.09 billion by 2035, expanding at a CAGR of 11.26% from 2026 to 2035. The genetic testing market is driven by rising demand for personalized medicine and early disease diagnosis.

Genetic Testing Market Key Takeaways

• By Region, North America held a majority revenue share of the Genetic Testing Market in 2025.
• By Region, Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By test type, the diagnostic testing segment held a dominant position in the market with a share in 2025.
• By test type, the prenatal & newborn testing segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
• By disease, the cancer segment accounted for a considerable revenue share in the market in 2025.
• By disease, the alzheimer's segment is expected to grow with the highest CAGR in the market during the studied years.

Advancing the Genetic Testing Market Through Genomic Innovation

The genetic testing market consists of diagnostic technologies based on the analysis of genes, chromosomes, RNA, or DNA to diagnose inherited diseases, mutations, treatments, and susceptibility to disease. Rising trends in personalized medicine, the growing incidence of genetic diseases, cancer, and ongoing development of next-generation sequencing and molecular diagnostics are driving rapid expansion of the market. The increasing value of prevention-led healthcare, positive government policies towards genomics research, and shrinking sequencing costs are contributing to growth in the market.

How has AI benefited the Market?

The speed, accuracy, and personalization of genetic testing systems are changing with the intervention of AI. It processes massive genomic datasets very fast-in a matter of seconds-manyfold faster than the traditional diagrammatic method; hence variations in genes and mutations causing diseases can be identified sooner, thus speeding up research, diagnostics, and drug discovery. Such a situation calls for treatment to be put into effect with less delay-either to prevent or restrict the progression of the disorder. The AI approach, which can recognize very subtle common patterns in genetic data, enables much-improved predictions of disease risk and treatment recommendations. By implementing personalized medicine, therapies can then be recommended that are specific to each patient based on the knowledge of the particular genes involved in their disorder, in this way minimizing the side effects of treatment options. It also helps in cost reductions with automation of complex analysis AIs that would otherwise be very expensive to have done. It can catch diseases early, allowing for preventative measures or correct treatments to be initiated. Hence, AI brings genetic testing on the platform of quick processing, greater accuracy, targeted therapies, and cost efficiencies, all along making healthcare a step ahead toward the domain of personalization.

Genetic Testing Market Growth Factors

The global genetic testing market is primarily driven by the rising prevalence of chronic and genetic diseases and the introduction of innovative testing kits owing to the technological advancements. The rising consumer awareness regarding the availability of advanced diagnostic tests is fueling the demand for the genetic testing. Moreover, growing geriatric population is expected to propel the market growth in the upcoming future. According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 ad this number is expected 2.1 billion by 2050. The old age people are prone to various chronic diseases, which can foster the demand for the genetic testing across the globe. The increased disposable income, rising consumer expenditure on healthcare, technological advancements, and easy availability of genetic testing services are the major factors that drive the growth of the genetic testing market across the globe.

The rising government initiatives to spread the awareness regarding the genetic testing are spurring the adoption of the genetic testing among the global population. Moreover, the presence of numerous top market players and their heavy investments in the research & development activities has encouraged innovation in the product design, improved distribution, and enhanced quality of the products. The growing popularity of the direct-to-consumer genetic testing kit has increased the adoption of the genetic testing kits among the population owing to its affordable costs, which is expected to boost the growth of the global genetic testing market. Moreover, the growing penetration of online websites like Ancestry.com and 23andme.com are popular for providing DNA testing kits to the consumers through home delivery. The ease and convenience associated with the self-testing kits is boosting the participation of people in the self-testing websites. Furthermore, the rising marketing activities adopted by the online websites has significantly played their part in spreading awareness regarding the genetic testing. For instance, Ancestry.com invested around US$ 109.0 million on TV ads in US, in 2016. These advertisements had played a crucial role in the development of the genetic testing market.

Major Trends Fuelling the Growth of the Genetic Testing Market

• The integration of artificial intelligence and big data allows for the use of AI and machine learning to improve the interpretation of genetic variants, decrease error rates, and accelerate the turnaround time for reports, particularly in oncology and profiling for rare diseases.
• The rapid growth of DTC testing through at-home testing kits enables consumers to access health, ancestry, wellness, and fitness genetic information directly without having to go through traditional clinical channels.
• In addition, there has been an increase in the adoption of DNA-based tests combined with personalized diet and lifestyle recommendations, which is leading to a growing number of consumers taking advantage of personalized wellness testing.
• Finally, due to convenience and changes in consumer behaviour that occurred during the COVID-19 pandemic, online and e-commerce channels now constitute a large share of global sales of genetic tests.
• New technologies such as liquid biopsies and multiplex platforms have enabled quicker diagnostic testing and created additional ability to guide patients into appropriate targeted therapy based on their genetic information.

Market Outlook

• Industry Growth Overview: Lower costs for genetic sequencing, options for payer reimbursement are steadily increasing for genetic testing, while information from genetics and genomics continues to transition into clinical care from the research setting.
• Sustainability Trends: Many companies within the genetic testing industry are implementing sustainable laboratory processes and utilizing digital reporting systems to reduce their physical waste. In addition, companies are using cloud-based data storage platforms to better manage their physical resources, as well as to minimize their carbon footprint by utilizing cloud services to access and share genomic and clinical data.
• Global Expansion: The majority of genetic testing growth is occurring in the Asia-Pacific and other developing economies. This growth is the result of government investments in national genomics projects, the advent of regulatory changes allowing for DTC genetic testing, and increased access to healthcare through expanding healthcare systems.
• Startup Ecosystem: Many early-stage companies are entering the genetic testing marketplace, with products focusing on genomic interpretation solutions, artificial intelligence-based diagnostic tools, and customized wellness testing systems. These companies are benefiting from a plethora of venture capital or other investments related to the healthcare technology sector.

Market Scope

Market dynamics

The factors that drive growth of the genetic testing market include increase in incidences of genetic disorders and cancers and rise in awareness & acceptance of personalized medicines. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals hamper the market growth. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players.

Drivers

Increase in incidences of genetic disorders and cancer Recently, increase in incidences of cancer and genetic conditions has been witnessed globally. According to the American Cancer Society, almost 1.8 million new cancers were diagnosed in 2020, with 606,520 cancer deaths in the U.S. Cancer is the second highest death-causing disease worldwide. Many types of cancers are inherited from generation to generation due to genes. Thus, genetic testing is widely applicable to study this pattern for prevention, treatment, and drug discovery. In addition, cytogenetics aid in the study of chromosomes to provide a better knowledge of cancers such as breast cancer.

• Increase in incidences of genetic disorders and cancer.
• Rise in awareness & acceptance of personalized medicines
• Advancements in genetic testing techniques

Restraints

• Standardization concerns of genetic testing-based diagnostics
• Stringent regulatory requirements for product approvals

Complexity of Genetic Data and Interpretation

Customer problems arising from complex genetic data indeed play a major constraint on genetic testing markets with vast data and complex genomic information. The genetic data are perplexing to healthcare personnel and patients sometimes. In many cases, one kind of gene variation cannot be evaluated with respect to its clinical meaning, so that practical and pertinent guidance cannot be offered to patients. These situations are sometimes vague concerning diagnosis and treatment decisions. On the contrary, standard protocol for the interpretation of gene test results is lacking, whereas divergent laboratories and practitioners provide so-called conflicting recommendations based on the cons of each interpretation, further growing the confusion and undermining confidence. This situation left the actual use of the test within a clinical setup in limbo; hence, acceptance and the potential benefits incumbent on the test in personalized medicine are compromised.

• Untapped emerging markets in developing countries

Personalized Medicines - Rise awareness & acceptance

Personalized medicine is based on the principle that each patient is different and requires individualistic drug treatment. Large-scale drug discovery is essential to increase the feasibility and practicality of personalized medicines for detection of diseases and disorders. Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. It helps in accelerating drug discovery and development. Moreover, researchers are aware that customized disease treatments are seemingly possible through various genetic testing techniques such as cytogenetic testing (fluorescence in situ hybridization, microarray, and others), biochemical testing, molecular testing, and DNA sequencing. Moreover, requests of patienst to primary care

physicians for genetic testing is anticipated to rise, especially from healthy adults seeking for early detection or prevention of genetic disorders. This trend is anticipated to boost the market growth during the forecast period.

In addition, consumer awareness of personalized medicines increased to 33% in 2019 from 29% in 2018. In addition, consumer awareness has only grown by around 1% year-over-year ever since 2013.

Advancements in genetic testing techniques

Technological advancements in genetic testing include development of next-generation sequencing and chromosomal microarray analysis, which transforms the method of determination of structural and numerical abnormalities in chromosomes and, in turn, lead to detection of various rare genomic and genetic disorders. Technologies also contribute toward development of non-invasive cffDNA (cell-free fetal DNA) for identifying sub-chromosomal abnormalities, single-gene disorders, and chromosomal aneuploidy. Further, these technologies contribute toward development of carrier screens that allow simultaneous detection of various genetic disorders.

Key companies are investing in development of genetic testing. For instance, in July 2020, Myriad Genetics, Inc. launched proprietary AMPLIFY technology, which increases performance of its Prequel noninvasive prenatal screening (NIPS) test. In addition, Myriad also launched New GeneSight psychotropic patient collection kit in June 2020. This kit allows DNA sample collection, typically administered in a clinician's office, to be completed at home.

Moreover, in September 2019, Roche launched a blood-based genomic profiling test, FoundationOne Liquid. This test can detect 70 most common mutated genes in solid tumors and microsatellite instability. In addition, in May 2020, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer, who have a germline BRCA mutation and are candidates for treatment with PARP (poly ADP ribose polymerase) inhibitor Lynparza (olaparib). These advancements in genetic testing products by major key players are projected to serve as growth factors for the cytogenetic market during the forecast period.

Opportunity

Untapped emerging markets in developing countries

Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure. In addition, emerging nations need to focus on costeffectiveness and scalability to cater to the needs of rising patient pool. In January 2017, the World Economic Forum in its project paper, Health Systems Advancing in Emerging Economies, stated that one-third of the global health expenditure would be focused on provision of healthcare services in emerging markets by 2023.

The need for genetic testing has increased in the scientific communities throughout the world, owing to rise in awareness of genetic disorders in developing economies. Ease and applicability of genetic testing methodologies have gradually benefitted R&D activities in Asia and other developing regions of the world.

Similarly, different genome-based projects in these regions, such as the China Genome, have stimulated the market growth.

Large population base, decrease in costs of genetic testing techniques, and rise in awareness about genetic disorders in Asia-Pacific are expected to provide numerous growth opportunities to the market players during the forecast period. For instance, in May 2020, Takara Bio USA, Inc. announced completion of a new GMP (Good Manufacturing Practice) facility for manufacturing gene and cell therapy products in Shiga, Japan.

Segmental Insights

Test Type Insights

The predictive testing segment is expected to grow steadily, with the rising awareness of risk for hereditary diseases and prevention of diseases. Predictive genetic tests are used to determine the probability of acquiring diseases like cancer, cardiovascular and neurological diseases. These tests are driving demand with the growth of personalized medicine. Genomic sequencing technologies have advanced and enhanced testing accuracy and affordability. The use of predictive testing is becoming more widespread in regularly conducted treatment in healthcare systems.

The carrier testing segment is projected to witness stable growth during the forecast period, driven by increasing uptake of family planning services and reproductive genetic testing. Carrier testing is used to identify someone who has inherited a genetic mutation before pregnancy. Awareness about inherited disorders among the future parents is propelling the growth. Carrier screening is beginning to be recommended by healthcare providers with prenatal/preconception care plans.

Disease Type Insights

The alzheimer's segment is expected to witness notable growth owing to the growing prevalence of neurodegenerative diseases and an early diagnosis trend. Genetic testing to determine if someone has inherited a risk factor for Alzheimer's disease. Growth in precision medicine and neurological research leading to increased investments is driving market expansion. Improvements in the discovery of biomarkers and the use of genomic technologies are enhancing the ability to diagnose.

The thalassemia segment is expected to grow steadily, due to rising prevalence of inherited blood disorders, especially in the Asian, Mediterranean, and Middle Eastern regions. With the use of genetic testing, early diagnosis of the disease and detection of carriers can be performed, and disease management carried out. An increasing number of government screening programs endorsement is contributing to broader acceptance. Volumes of testing are also continuing to rise due to prenatal and newborn screening programs.

The cystic fibrosis segment is projected to witness stable growth during the forecast period with stable growth in cystic fibrosis. Genetic testing has an important role in the early diagnosis and planning for care. Increasing recognition and understanding of inherited respiratory disorders are complementing sales. Rising awareness and understanding of inherited respiratory disorders are supporting sales. Genetic testing – present in routine clinical practice.

Regional Insights

North America Dominates the Global Genetic Testing Market

North America dominated the global genetic testing market with the highest revenue share of 54% in 2025. In terms of revenue and is estimated to sustain its dominance during the forecast period. This can be attributed to the increased consumer awareness regarding the benefits of genetic testing among the population. Moreover, the easy availability of self-testing kits through online websites in the nation like US has boosted the adoption of the genetic testing kits among the population. Moreover, the increased prevalence of various chronic diseases among the majority of the population coupled with increased consumer expenditure on healthcare has exponentially boosted the market growth. The rising number of geriatric people in US is expected to drive the market in the forthcoming years. Furthermore, the rising popularity and adoption of personalized medicines among the population is expected to foster the market growth.

U.S. Genetic Testing Market Size and Growth 2026 to 2035

U.S. market is anticipated to grow significantly, due to the high adoption of precision medicine and sophisticated genomic technologies. The country has a strong genetic testing laboratory and health care system. With inherited diseases and cancer becoming more prevalent, the market for genetic screening is expected to grow. The government funds genomics studies, encouraging innovations. Pharmacogenomic testing is becoming increasingly used, which increases the range of clinical use. There are also leading diagnostic and biotechnology companies that add to the market's growth.

The U.S. genetic testing market was valued at USD 6.26 billion in 2025 and is expected to surpass USD 27.11 billion by 2035, poised to grow at a CAGR of 11.34% between 2026 to 2035.

What Makes Asia Pacific the Most Opportunistic Market for Genetic Testing?

On the other hand, the Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is characterized by the presence of huge population, rising prevalence of chronic diseases, and growing awareness regarding the genetic testing. The increasing disposable income and rising healthcare expenditure is further expected to drive the growth of the market.

China is the major contributor to the Asia Pacific genetic testing market due to its large population base, strong government support for genomics and precision medicine initiatives, and rapidly expanding healthcare infrastructure. Significant investments in biotechnology, widespread adoption of advanced sequencing technologies, and the presence of leading domestic genetic testing companies further strengthen China's dominant position in the regional market.

What Makes Europe a Notably Growing Region in the Genetic Testing Market?

Europe is expected to grow at a notable rate in the market. This is due to the rising prevalence of genetic disorders, the increasing adoption of genetic testing for disease diagnosis, and rapid advancements in genetic testing technologies. Technological advancements, including next-generation sequencing (NGS) and polymerase chain reaction (PCR), are gaining traction in the region. These advancements have improved the accuracy, speed, and cost-effectiveness of genetic testing, thereby propelling the market forward. The region also boasts several key players who offer a wide range of genetic testing products and services. Additionally, the region also benefits from supportive government initiatives that help promote genetic testing and personalized medicine.

Germany Market Trends

Germany market is anticipated to grow significantly. The demand for personalized medicine is aiding in the adoption of genetic testing. It is clear that government funding of biomedical research and research and development is contributing to a strengthening of innovation. An increase in hereditary diseases and cancer is helping to drive testing demand. The adoption of routine clinical use of genomic diagnostics is underway in healthcare sectors. There are steady improvements in diagnostics efficiency through new and evolving technology.

What Potentiates the Genetic Testing Market in Latin America?

The market in Latin America is driven by technological innovations, the increasing awareness of personalized medicine, and the growing use of genetic data in medical and research applications. The region has been growing steadily as advancements in genomics, next-generation sequencing (NGS), and bioinformatics help make genetic tests more accurate, accessible, and affordable. Moreover, factors such as rising demand for preventive healthcare and increasing awareness of the role of genetics in disease prevention further drive the market.

Brazil Market Trends

Brazil genetic testing market is anticipated to grow significantly, due to the expansion of molecular diagnostics and the enhancement of healthcare infrastructure. Diseases and disorders, and the growing awareness of them, are driving demand for genetic screening. Governments have made efforts to support public healthcare, and this is helping increase adoption. Testing at private diagnostic labs is growing. The market is getting robust due to growing investments in precision medicine. The increasing uptake of prenatal and oncology testing is also driving sales.

What Opportunities Exist in the Middle East & Africa?

The Middle East & Africa (MEA) offers significant opportunities in the genetic testing market due to increasing healthcare investments, the rising awareness of genetic disorders, and advancements in medical technology. The rapid expansion of healthcare infrastructure, along with a growing focus on personalized medicine and preventive care, also opens new avenues for growth. Government initiatives and rising demand for genetic testing services also contribute to the region's market growth.

Saudi Arabia Market Trends

Saudi Arabia market is anticipated to grow significantly, due to government funding for genomic medicine and modernization of healthcare systems. Genetic tests are being adopted more widely at the national level by screening programs. An increase in the incidence of inherited genetic disorders is fuelling diagnostic demand. The rising knowledge of preventative healthcare is promoting early screening. The development of sophisticated laboratories is helping to make services available. The healthcare transformation programmes are fuelling innovation as part of precision medicine programmes.

Value Chain Analysis

• R&D: The core of the research is biomarker discovery, genomic sequencing technologies, assay development, and bioinformatic platforms with long-term goals to increase the accuracy of diagnostic procedures, improve clinical applications of current diagnostics, and implement personalized medicine applications.
  • Key Players: Thermo Fisher Scientific, Roche, QIAGEN.
• Clinical Trials and Regulatory Approvals: Tests achieve test validation parameters from studies that have been performed in a clinical environment: reliability, safety, and effectiveness, before reaching the level of regulatory approval from various authorities and therefore can be commercialized in clinical laboratories as well as laboratories used for diagnosis.
  • Key Players: Labcorp, Quest Diagnostics, Guardant Health, Myriad Genetics.
• Distribution to Hospitals and Pharmacies: Healthcare providers, hospitals, diagnostic laboratories, speciality clinics and pharmacy networks are channels of distribution for testing kits and laboratory consumables for timely access to patients.
  • Key Players: Thermo Fisher Scientific, Abbott, Bio-Rad Laboratories, Danaher Corporation.
• Patient Support and Services: These services enable genetic counsellors to assist in optimal clinical decisions and personalized care plans through genetic counselling, interpr

Collaboration Landscape

• In June 2026, AI genomics consortium was launched at the AI x BIO conference by Wellcome Sanger Institute, Google DeepMind and Google.org. The partnership will focus on the creation of AI-ready biological datasets in support of sophisticated machine learning models to enable discoveries in biology and biomedical sciences to be made faster. (Source: https://www.sanger.ac.uk)
• In June 2026, Hartwig Medical Foundation entered a strategic partnership with the launch of the Ultima UG200™ sequencing system. The collaboration aims to bring the advantages of WGS to a broader, larger scale of oncology patients, making it more accessible, scalable, and clinically actionable. (Source: https://www.prnewswire.com)
• In April 2026, PacBio and Lucid Genomics GmbH announced a compatibility collaboration through the PacBio Compatible partner program. The partnership brings together Lucid's Bioinformatics platforms with PacBio long-read sequencing technologies to further support research and clinical genomics tertiary genomic data analysis. (Source: https://www.pacb.com)

Competitive Landscape

The genetic testing market is highly competitive and innovative, with established diagnostics companies competing to bring innovation in the sequencing technologies, molecular diagnostics, and precision medicine. Product development and strategic alliances, clinical research, and genetic testing portfolio expansion are practical moves key players are making to bolster market positions, among Genentech Inc., Sorenson Genomics LLC, Abbott Molecular, and Bayer Diagnostics.

Furthermore, the partnerships with research institutes, health care organizations, and biotech companies are accelerating technology adoption and adding point-of-service access to advanced genetic testing providers. Expansion in the areas of early disease diagnosis, oncology, reproductive, and pharmacogenomics is driving competition and innovation in the global marketplace.

Genetic Testing Market Companies

• Genentech Inc.
• Sorenson Genomics, LLC
• Abbott Molecular
• Bayer Diagnostics
• Biocartis
• BioHelix
• Celera Genomics
• Genomic Health
• HTG Molecular Diagnostics
• PacBio

Recent Developments

• In April 2026, Fortis Hospitals, Bengaluru, opened its network Preventive Genomics Clinic, which will be the first of its kind to further its mission in preventive and precision healthcare. Coaches to greater Generative testing and Personalised care in early disease detection. (Source: https://www.expresshealthcare.in)
• In October 2025, at the American Society of Human Genetics (ASHG) 2025 Meeting in Boston, Genomics introduced Mystra, an AI-powered human genetics platform. The platform will be used to help accelerate drug research and validation using large genomics human genome data. (Source: https://www.genomics.com)
• In May 2025, Centogene announced the launch of its new Reproductive Genetics Portfolio, including both Preimplantation Genetic Testing for Aneuploidy (PGT-A) and comprehensive carrier screening services. The PGT-A test, strengthened by CENTOGENE's database of over one million sequences, provides high sensitivity, diagnostic accuracy, and an optional rapid turnaround of up to 24 hours for IVF embryos.
  (Source: centogene.com)
• In May 2025, Hydreight Technologies, a leading digital health platform, launched a new direct-to-consumer genetic testing and personalized wellness solution via its VSDHOne platform.
  (Source: globenewswire.com)
• In January 2025, the PGIMER, in partnership with the Punjab government, launched the DBT-UMMID initiative to improve genetic disorder healthcare services in Moga.
  (Source: hindustantimes.com)

Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

In August 2020, Guardant Health acquired the approval from FDA for its Guardant 360 CDx.

The various developmental strategies like acquisition, partnerships, mergers, and government policies fosters market growth and offers lucrative growth opportunities to the market players.

Segments Covered in the Report

By Test Type

• Carrier Testing
• Predictive Testing
• Diagnostic Testing
• Prenatal & Newborn Testing
• Nutrigenomics
• Pharmacogenomics
• Others

By Disease

• Cancer
• Alzheimer's
• Thalassemia
• Cystic Fibrosis
• Huntington's Disease
• Duchenne Muscular Dystrophy
• Other Diseases

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa